The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial.
Marcia S. Brose
Consultant or Advisory Role - Bayer; Onyx
Honoraria - Bayer
Research Funding - Bayer
Barbara Jarzab
Honoraria - Bayer
Rossella Elisei
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Salvatore Siena
No relevant relationships to disclose
Lars Bastholt
Consultant or Advisory Role - Bayer (U)
Honoraria - Bayer
Christelle De La Fouchardiere
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Furio Pacini
Consultant or Advisory Role - Bayer
Ralf Paschke
Other Remuneration - Bayer
Christopher Nutting
Honoraria - Bayer
Young Kee Shong
No relevant relationships to disclose
Steven I. Sherman
Consultant or Advisory Role - Amgen; AstraZeneca; Bayer; Eisai; Exelixis; Pfizer; Roche
Honoraria - Bayer; Exelixis
Research Funding - Amgen
Other Remuneration - Exelixis
Johannes WA Smit
No relevant relationships to disclose
John Woojune Chung
Employment or Leadership Position - Bayer
Christian Kappeler
Employment or Leadership Position - Bayer Schering Pharma
Istvan Molnar
Employment or Leadership Position - Bayer
Martin Schlumberger
Consultant or Advisory Role - AstraZeneca; Bayer; Eisai; Genzyme
Honoraria - AstraZeneca; Bayer; Eisai; Genzyme; SOBI
Research Funding - AstraZeneca; Bayer; Eisai; Genzyme